Alkermes (ALKS) Other Operating Expenses (2010 - 2026)
Alkermes' (ALKS) quarterly Other Operating Expenses came in at $228.8 million in Q1 2026, up 32.93% year-on-year from $172.1 million in Q1 2025, and up 129.06% on a QoQ basis from -$787.3 million in Q4 2025.
Alkermes (ALKS) Other Operating Expenses (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has 17 years of Other Operating Expenses data on file, last reported at $228.8 million in Q1 2026.
- On a quarterly basis, Other Operating Expenses rose 32.93% year-over-year to $228.8 million in Q1 2026; TTM through Mar 2026 was -$633.6 million, a 2162.91% decrease from a year earlier, with the FY2025 full-year figure at -$1.2 billion, down 2667.28% from the prior year.
- Other Operating Expenses for Q1 2026 stood at $228.8 million, up from -$787.3 million in the prior quarter.
- Over the last five years, Other Operating Expenses for ALKS reached as high as $569.3 million in Q4 2023 and fell as low as -$787.3 million in Q4 2025.
- Historically, Other Operating Expenses has averaged $2.4 million across 5 years, with a median of $64.2 million in 2023.
- Across the five-year window, Other Operating Expenses slumped 1591.94% in 2022 and soared 8192.76% in 2023, its largest moves.
- Year by year, Other Operating Expenses stood at -$3.6 million in 2022, then surged by 16122.4% to $569.3 million in 2023, then tumbled by 157.25% to -$325.9 million in 2024, then sank by 141.56% to -$787.3 million in 2025, then surged by 129.06% to $228.8 million in 2026.
- Per Business Quant data, the three most recent Other Operating Expenses figures were $228.8 million in Q1 2026, -$787.3 million in Q4 2025, and $167.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn |
| 10 | Alkermes | 8.78 Bn | 8.27 Bn | 331.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 228.82 Mn |
| Dec 31, 2025 | -787.26 Mn |
| Sep 30, 2025 | 167.22 Mn |
| Jun 30, 2025 | -242.34 Mn |
| Mar 31, 2025 | 172.13 Mn |
| Dec 31, 2024 | -325.91 Mn |
| Sep 30, 2024 | 123.01 Mn |
| Jun 30, 2024 | 61.49 Mn |
| Mar 31, 2024 | -116.32 Mn |
| Dec 31, 2023 | 569.28 Mn |
| Sep 30, 2023 | 70.49 Mn |
| Jun 30, 2023 | 72.15 Mn |
| Mar 31, 2023 | 66.96 Mn |
| Sep 30, 2022 | -3.55 Mn |
| Jun 30, 2022 | 870,000.00 |
| Mar 31, 2022 | -19.07 Mn |
| Dec 31, 2021 | -750,000.00 |
| Sep 30, 2021 | -5.20 Mn |
| Jun 30, 2021 | 3.24 Mn |
| Mar 31, 2021 | 1.28 Mn |